Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Work In Process (2016 - 2020)

United Therapeutics (UTHR) has disclosed Work In Process for 11 consecutive years, with $28.1 million as the latest value for Q1 2020.

  • Quarterly Work In Process rose 6.84% to $28.1 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $28.1 million through Mar 2020, up 6.84% year-over-year, with the annual reading at $29.1 million for FY2019, 3.93% up from the prior year.
  • Work In Process hit $28.1 million in Q1 2020 for United Therapeutics, down from $29.1 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $29.8 million in Q3 2019 to a low of $22.9 million in Q1 2017.
  • Historically, Work In Process has averaged $26.2 million across 5 years, with a median of $26.2 million in 2016.
  • Biggest five-year swings in Work In Process: grew 21.29% in 2016 and later dropped 13.33% in 2017.
  • Year by year, Work In Process stood at $24.9 million in 2016, then fell by 3.21% to $24.1 million in 2017, then increased by 16.18% to $28.0 million in 2018, then increased by 3.93% to $29.1 million in 2019, then dropped by 3.44% to $28.1 million in 2020.
  • Business Quant data shows Work In Process for UTHR at $28.1 million in Q1 2020, $29.1 million in Q4 2019, and $29.8 million in Q3 2019.